Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy

Clinical Infectious Diseases

Volumn 41, Issue 12, 2005, Pages 1697-1705

  Welte, Tobias ^a   Petermann, Wolfgang ^b   Schürmann, Dirk ^c   Bauer, Torsten Thomas ^d   Reimnitz, Peter ^e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Medical Clinic   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; ERYTHROMYCIN; GAMMA GLUTAMYLTRANSFERASE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; CHILL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LEUKOCYTOSIS; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARENTERAL DRUG ADMINISTRATION; PHLEBITIS; PLEURISY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RIGOR; SPUTUM; SYMPTOM; TACHYPNEA; THORAX PAIN; VOMITING;

ADMINISTRATION, ORAL; AGED; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CEFTRIAXONE; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; ERYTHROMYCIN; FEMALE; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PARENTERAL NUTRITION; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; QUINOLINES; REMISSION INDUCTION; TIME FACTORS;

EID: 28744456644     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/498149     Document Type: Article

References (22)

1. Ewig S, Reinert RR, Wiedemann B, et al. Antibiotika-Resistenz bei Erregern ambulant erworbener Atemwegsinfektionen. Chemotherapie Journal 2002; 11:12-26. Available at: http://www.wissenschaftliche-verlagsgesellschaft.de/CTJ/ CTJ2002/CTJ1-02/012-026.pdf. Accessed 18 February 2005.
2. Welte T, Suttorp N, Marre R. CAPNETZ-community-acquired pneumonia competence network. Infection 2004; 32:234-8.
3. American Thoracic Society. Guidelines for initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-26.
4. Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31:347-82.
5. Mandell L, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-33.
6. Loddenkemper R, Gibson GJ, Sibille Y, eds. European lung white book. Sheffield, United Kingdom: ERSJ, 2003:64.
7. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562-72.
8. Finch R, Schürmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46:1746-54.
9. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998; 11:986-91.
10. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2001; 163:1730-54.
11. Agence Française de Sécurité Sanitaire des Produits de Santé. Antibiotherapie par voie generale en pratique courante: infections respiratoires basses de l'adulte. 24 January 2003. Available at: http:// www.agmed.sante.gouv.fr/pdf/5/rbp/irbcomp_ad.pdf. Accessed 18 February 2005.
12. Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003; 21:135-43.
13. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-50.
14. Barlow GD, Lamping DL, Davey PG, Nathwani D, Evaluation of outcomes in community-acquired pneumonia: a guide for patients, physicians, and policy-makers. Lancet Infect Dis 2003; 3:476-88.
15. Lorenz J, Busch W, Thate-Waschke IM. Moxifloxacin in acute exacerbations of chronic bronchitis: clinical evaluation and assessment by patients. BRONCHIMOX Study Group, J Int Med Res 2001; 29:61-73.
16. Lorenz J, Thate-Waschke IM, Mast O, et al. Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. J Int Med Res 2001; 29:74-86.
17. Marrie T, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000; 283:749-55.
18. Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 2001; 111: 367-74.
19. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-37.
20. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752-60.
21. Genné D, Kaiser L, Kinge TN, Lew D. Community-acquired pneumonia: causes of treatment failure in patients enrolled in clinical trials. Clin Microbiol Infect 2003; 9:949-54.
22. Juthani-Mehta M, Quagliarello VJ. Prognostic scoring systems for infectious diseases: their applicability to the care of older adults. Clin Infect Dis 2004; 38:692-6.